Drug Profile
GL 101
Alternative Names: GL101Latest Information Update: 26 Feb 2019
Price :
$50
*
At a glance
- Originator Glia LLC.
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Corneal disorders
Most Recent Events
- 26 Feb 2019 Discontinued - Phase-II for Corneal disorders (Treatment-experienced) in USA (Topical)